No Data
No Data
Twist Bioscience Analyst Ratings
Natera Analyst Ratings
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
103721817 : stock exchange
Boganji4 : hello
curiousq : Bought some TMF last month, started to gain